AZILECT^® is the first once-daily treatment for people with Parkinson's disease

A therapy that brings together efficacy and convenient dosing.

AZILECT^® is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT^® was shown in patients with early PD who were receiving AZILECT^® as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT^® as adjunct therapy was shown in patients with PD who were treated with levodopa.

Read more in the Question and Answer Brochure.

In order to view the brochure, you will need Adobe^® Reader^®. For a FREE download of Adobe^® Reader^®, click here.

08291109/080219